Amgen/Wyeth Expand Enbrel Psoriatic Arthritis Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies have added a claim for improvement of physical function in patients with psoriatic arthritis as well as two-year radiographic data demonstrating inhibition of joint destruction progression.
You may also be interested in...
J&J's Remicade Adds Psoriatic Arthritis Indication
FDA approves the supplemental indication for infliximab; J&J plans to differentiate Remicade from Amgen/Wyeth's Enbrel by highlighting Psoriasis Area Severity Index score improvements and reduction of symptoms of dactylitis and enthesopathy.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.